GT Medical lands $10m Series A for IsoRay ’ s GammaTile

GT Medical Technologies said today that it landed a $10 million Series A round for the GammaTile brachytherapy it co-developed with IsoRay (NYSE:ISR) to treat brain tumors. Richland, Wash.-based IsoRay and the Barrow Neurological Institute formed GT Medical to develop the technology to embed Cesium-131 brachytherapy seeds in collagen tiles to treat malignant meningioma, according to regulatory filings, inking a formal co-development deal in March 2017. By January of the following year the deal had expanded to include an exclusive, 10-year manufacturing &supply pact for GammaTile. In July 2018 GammaTile won 510(k) clearance from the FDA. Today GT Medical said proceeds from the Series A round, led by MedTech Venture Partners with participation from BlueStone Venture Partners, are earmarked for further GammaTile commercialization. The device is already under limited release. “GammaTile Therapy was developed by a team of brain tumor specialists who were running out of options for their patients. Their urgency to find a viable solution for these patients led to the creation of GammaTile Therapy, which is designed to be immediate, safe, predictable, and effective,” GT Medical president &CEO Matthew Likens said in prepared remarks. “With this funding, in addition to adding seasoned industry executives to our team, we look forward to building and expanding our commercialization efforts so that we can offer this new option to pat...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Radiosurgery/Radiation therapy Wall Street Beat GT Medical Technologies IsoRay Source Type: news

Related Links:

We present a two parts review discussing the unique features of the elderly patient harboring an intracranial neoplasm. In this Part-I, we review the management of benign meningioma in the elderly population.Meningioma is the second most common primary brain tumor. The risk of developing meningioma increases dramatically after 65 years of age. Predicting a specific meningioma’s growth pattern and clinical behavior is impossible. Clinicians must choose between GTR with associated morbidity/ mortality, SRS or a combined AHS approach, since progression rates after STR are high. Several scoring systems attempt to offer...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Authors: Martelli C, Serra R, Inserra I, Rossetti DV, Iavarone F, Vincenzoni F, Castagnola M, Urbani A, Tamburrini G, Caldarelli M, Massimi L, Desiderio C Abstract Although histologically benign, adamantinomatous craniopharyngioma (AC) pediatric brain tumor is a locally aggressive disease that frequently determines symptoms and hormonal dysfunctions related to the mass effect on the surrounding structures. Another typical feature of this benign neoplasm is the presence of voluminous liquid cysts frequently associated with the solid component. Even if studies have been devoted to the proteomic characterization of th...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Derin Gebhardt, 37, from Roundup, Montana, was diagnosed in May 2017 with a pituitary tumor, which was causing a decrease in normal levels of sex hormones and behind his infertility.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
A team at Tampere University, Finland has developed a technique using surgical smoke that allows neurosurgeons to ID cancerous tissue during surgery. A new method developed by researchers at Tampere University in Finland helps analyze surgical smoke to distinguish between malignant tissue and health tissue. The researcher’s work was recently published in the Journal of Neurosurgery. The technology is based on differential mobility spectrometry, wherein flue gas ions are fed into an electric field. The distribution of ions in the electric field is tissue-specific, and the tissue can be identified on the ba...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Chow Peter D. Chang Radiographic assessment with magnetic resonance imaging (MRI) is widely used to characterize gliomas, which represent 80% of all primary malignant brain tumors. Unfortunately, glioma biology is marked by heterogeneous angiogenesis, cellular proliferation, cellular invasion, and apoptosis. This translates into varying degrees of enhancement, edema, and necrosis, making reliable imaging assessment challenging. Deep learning, a subset of machine learning artificial intelligence, has gained traction as a method, which has seen effective employment in solving image-based problems, including those in me...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: The authors' results show that surgical smoke from various brain tumors has distinct DMS profiles and the DMS analyzer connected to a special sampling system can differentiate between tumorous and nontumorous tissue and also between different tumor types ex vivo. PMID: 31200382 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
This article aims to credit Bailey for his pioneering definition of craniopharyngiomas as tumors with a true intrahypothalamic position. PMID: 31200375 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
Conclusion: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusions: This study suggests that p62 is an effector for HMGB1-induced EMT, and may represent a novel therapeutic target in GBM.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: The results clearly indicated that a combination of 68Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
More News: Brachytherapy | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Funding | Men | Neurology | Radiation Therapy | USA Health